Form 4: Belite Bio Insider Sells Shares Under 10b5-1 Plan

Belite Bio's Chief Scientific Officer, Nathan L. Mata, sold a significant number of American depositary shares under a pre-arranged trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., reported the sale of American depositary shares on April 21, 2026.
• These sales were executed as part of a Rule 10b5-1 trading plan adopted on December 10, 2025.
• The total number of shares sold is not explicitly stated but can be inferred from the reduction in beneficial ownership.
• The sales occurred at weighted average prices ranging from $163.26 to $167.94 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sales were conducted under a pre-arranged 10b5-1 plan, mitigating concerns about insider trading based on new information.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established plan.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which solely reports past transactions.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to allow executives to diversify their holdings or meet financial obligations without being perceived as trading on material non-public information. However, the volume and timing of such sales can still influence investor sentiment.

Stakeholder Impact

• Shareholders: May observe a slight increase in the float of shares available for trading. The pre-planned nature of the sale aims to minimize negative price impact, but significant sales can still affect market perception.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Trading, Rule 10b5-1, Share Sale, Securities and Exchange Commission, Nathan L. Mata